Sunday, August 11, 2024 6:00:08 AM
Beartrap’s
ACTUALLY 3 yearS ago DEFIES the above: 3200 YR
https://www.ucl.ac.uk/news/2021/jul/brain-cancer-trial-recruits-largest-ever-number-patients
That was in UCL lead investigator Dr Paul Mulholland’s GBM trial
The juxtaposition of EDEN units to ACTUAL size of UK market is a widening fault.
Also
DAY of INFAMY for DARK FORCES & WallSt collusion in NUKED NWBO shares
https://nwbio.com/presentation-about-phase-3-trial-of-dcvax-l-for-glioblastoma/
May 10, 2022 77 mln shs traded: Hi ~$2.00 Low ~38 cents
re Yahoo Finance HIstorical price data
That despite pleas by The MAESTRO for a HALT in trading
the collusionary DARK Forces & WallSt prevailed
Over the substitute for Dr. Linda Liau NYAS Presentation was Dr Paul McHolland
DIFFERENT STROKES for DIFFERENT FOLKS
The BANTER is getting there.
I say this because the UK, according to statistics, has about 1,500 new GBM patients a year The artisan method will only handle about 500 per year
So without Eden units up and running, we immediately start out overwhelmed in the manufacturing of our product.
ACTUALLY 3 yearS ago DEFIES the above: 3200 YR
Glioblastoma is a very aggressive brain tumour with around 2,200 cases diagnosed each year in England (AND around 3,200 across the UK).
https://www.ucl.ac.uk/news/2021/jul/brain-cancer-trial-recruits-largest-ever-number-patients
That was in UCL lead investigator Dr Paul Mulholland’s GBM trial
The juxtaposition of EDEN units to ACTUAL size of UK market is a widening fault.
Also
DAY of INFAMY for DARK FORCES & WallSt collusion in NUKED NWBO shares
https://nwbio.com/presentation-about-phase-3-trial-of-dcvax-l-for-glioblastoma/
May 10, 2022 77 mln shs traded: Hi ~$2.00 Low ~38 cents
re Yahoo Finance HIstorical price data
That despite pleas by The MAESTRO for a HALT in trading
the collusionary DARK Forces & WallSt prevailed
Over the substitute for Dr. Linda Liau NYAS Presentation was Dr Paul McHolland
DIFFERENT STROKES for DIFFERENT FOLKS
The BANTER is getting there.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
